Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
SGYP's Cash to Debt is ranked higher than
90% of the 926 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. SGYP: No Debt )
SGYP' s 10-Year Cash to Debt Range
Min: 0.13   Max: No Debt
Current: No Debt

F-Score: 3
Z-Score: -6.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -170.45
SGYP's ROE (%) is ranked lower than
53% of the 895 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. SGYP: -170.45 )
SGYP' s 10-Year ROE (%) Range
Min: -899.32   Max: -154.96
Current: -170.45

-899.32
-154.96
ROA (%) -128.05
SGYP's ROA (%) is ranked lower than
54% of the 930 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.82 vs. SGYP: -128.05 )
SGYP' s 10-Year ROA (%) Range
Min: -6858.53   Max: -112.99
Current: -128.05

-6858.53
-112.99
ROC (Joel Greenblatt) (%) -14383.82
SGYP's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.02 vs. SGYP: -14383.82 )
SGYP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -423053.33   Max: -20132.79
Current: -14383.82

-423053.33
-20132.79
EBITDA Growth (3Y)(%) 29.00
SGYP's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. SGYP: 29.00 )
SGYP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 122.4
Current: 29

0
122.4
EPS Growth (3Y)(%) 29.00
SGYP's EPS Growth (3Y)(%) is ranked higher than
90% of the 667 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.10 vs. SGYP: 29.00 )
SGYP' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 122.4
Current: 29

0
122.4
» SGYP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

SGYP Guru Trades in Q4 2013

Jim Simons 208,600 sh (New)
» More
Q1 2014

SGYP Guru Trades in Q1 2014

Jim Simons 197,390 sh (-5.37%)
» More
Q2 2014

SGYP Guru Trades in Q2 2014

Paul Singer 450,400 sh (unchged)
Jim Simons Sold Out
» More
Q4 2014

SGYP Guru Trades in Q4 2014

Jim Simons 162,095 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with SGYP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 16.70
SGYP's P/B is ranked higher than
51% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. SGYP: 16.70 )
SGYP' s 10-Year P/B Range
Min: 0   Max: 46.2
Current: 16.7

0
46.2
EV-to-EBIT -3.01
SGYP's EV-to-EBIT is ranked higher than
64% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.09 vs. SGYP: -3.01 )
SGYP' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -3.01

Current Ratio 1.98
SGYP's Current Ratio is ranked higher than
66% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.36 vs. SGYP: 1.98 )
SGYP' s 10-Year Current Ratio Range
Min: 0.04   Max: 11.88
Current: 1.98

0.04
11.88
Quick Ratio 1.98
SGYP's Quick Ratio is ranked higher than
73% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. SGYP: 1.98 )
SGYP' s 10-Year Quick Ratio Range
Min: 0.04   Max: 11.88
Current: 1.98

0.04
11.88

Valuation & Return

vs
industry
vs
history
Price/Net Cash 22.10
SGYP's Price/Net Cash is ranked higher than
89% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. SGYP: 22.10 )
SGYP' s 10-Year Price/Net Cash Range
Min: 4.63   Max: 581.6
Current: 22.1

4.63
581.6
Price/Net Current Asset Value 22.10
SGYP's Price/Net Current Asset Value is ranked higher than
82% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. SGYP: 22.10 )
SGYP' s 10-Year Price/Net Current Asset Value Range
Min: 4.63   Max: 301.65
Current: 22.1

4.63
301.65
Price/Tangible Book 16.60
SGYP's Price/Tangible Book is ranked higher than
57% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.29 vs. SGYP: 16.60 )
SGYP' s 10-Year Price/Tangible Book Range
Min: 4.44   Max: 517.9
Current: 16.6

4.44
517.9
Earnings Yield (Greenblatt) -30.10
SGYP's Earnings Yield (Greenblatt) is ranked lower than
53% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SGYP: -30.10 )
SGYP' s 10-Year Earnings Yield (Greenblatt) Range
Min: -36.2   Max: 0
Current: -30.1

-36.2
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:S90.Germany,
Synergy Pharmaceuticals, Inc., was incorporated under the laws of the State of Florida on November 15, 2005 as Pawfect Foods, Inc. The Company is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. Its product candidate is plecanatide, a guanylate cyclase C, or GC-C, receptor agonist, to treat GI disorders, primarily chronic idiopathic constipation, or CIC, and constipation-predominant- irritable bowel syndrome, or IBS-C. CIC and IBS-C are functional gastrointestinal disorders that afflict millions of sufferers worldwide. CIC is primarily characterized by constipation symptoms but a majority of these patients report experiencing straining, bloating and abdominal discomfort as among their most bothersome symptoms. IBS-C is characterized by frequent and recurring abdominal pain and/or discomfort associated with chronic constipation. The Company's main competitors include major pharmaceutical and biotechnology companies focusing on GI such as Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., and Takeda. The Company is subject to various environmental, health and safety regulations including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials.
» More Articles for SGYP

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
5 Stocks Under $10 Set to Soar: Sportsman's Warehouse and More Feb 26 2015
Synergy Pharmaceuticals to Present at Two Upcoming Investment Conferences Feb 03 2015
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 29 2015
Synergy Pharmaceuticals Completes Patient Enrollment for the Second Pivotal Phase 3 Trial of... Jan 29 2015
ContraVir to Present at Noble Financial Conference Jan 15 2015
ContraVir Pharmaceuticals Appoints John Sullivan-Bolyai, M.D., MPH, as Chief Medical Officer Jan 13 2015
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 09 2015
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 08 2015
ContraVir Pharmaceuticals adds Renu Gupta, M.D., to Scientific Advisory Board Jan 08 2015
Synergy Pharmaceuticals Completes Patient Enrollment for the First Pivotal Phase 3 Trial of... Jan 08 2015
Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug... Dec 18 2014
Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial of Plecanatide in Patients with... Dec 18 2014
Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug... Dec 18 2014
ContraVir Pharmaceuticals Appoints Nathaniel Katz, M.D., Chairman of New Scientific Advisory Board Dec 16 2014
Synergy Pharmaceuticals Drug Fares Well in Phase II Study Nov 20 2014
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 19 2014
Synergy Pharmaceuticals Announces Positive Results of SP-333 Phase 2 Trial in Patients with... Nov 19 2014
SYNERGY PHARMACEUTICALS, INC. Financials Nov 18 2014
Synergy Pharma posts 3Q loss Nov 10 2014
Synergy Pharma posts 3Q loss Nov 10 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK